Zymeworks
- Biotech or pharma, therapeutic R&D
Zymeworks (Nasdaq: ZYME) is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. We are focused on moving novel therapeutics into the clinic in 2024 and 2025, including ZW191, a best-in-class FRα-targeting ADC now in first-in-human studies, and ZW251, a GPC3-targeting ADC planned for 2025—both leveraging our proprietary TOPO1i payload, ZD06519. We are also advancing next-generation multispecific antibodies, including ZW171, a 2+1 mesothelin-directed T-cell engager that entered the clinic in 2024, and ZW209, a preclinical DLL3-targeting trispecific TCE incorporating CD28 co-stimulation.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}